Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 10, 2022--Company to Host Conference Call May 16, 2022, at 8:30AM ET--
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company today announced that management will report first quarter 2022 financial results prior...
-
April 21, 2022•Breakthrough Therapy designation was requested based on data from post-hoc analysis of patients who in addition to Aviptadil or placebo were also treated with Remdesivir and whose respiratory failure due to Critical COVID-19 continued to progress.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, today announced that it has filed a new Breakthrough Therapy designation request with...
-
April 8, 2022Company to Present Corporate Update During Investor Webcast, April 14, 2022, at 4:30pm ET
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, today announced its interim Chief Executive Officer, Robert Besthof, and other...
-
March 31, 2022Company to Host Conference Call and Webcast March 31, 2022, at 8:30am ET
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, today announced its financial results for the year ended December 31, 2021 and...
-
March 28, 2022--Company to Host Conference Call March 31, 2022, at 8:30AM ET---
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company today announced that management will report year end 2021 financial results prior to...
-
March 18, 2022
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage pharmaceutical company, announced today that the company's Board of Directors appointed Ira Strassberg as Chief Financial Officer and...
-
March 8, 2022Robert Besthof, Head of Operations and Chief Commercial Officer, Appointed Interim CEO Jonathan Javitt, MD, MPH, to Serve as a Consultant and Chief Scientist and Remain on the Board of Directors
NRx Pharmaceuticals (Nasdaq: NRXP) ("NRx" or the "Company"), a clinical-stage, biopharmaceutical company, today announced that Jonathan Javitt, MD, MPH, has retired as Chief Executive Officer...
-
February 15, 2022- After review of more than 448 enrolled patients in ACTIV-3b Critical Care Study, no new safety concerns identified by Independent Data Safety Monitoring Board; study cleared to continue enrollment to 640 Patients
NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today announced results of a review conducted by the Therapeutics and Prevention Data Safety and Monitoring Board...
-
February 11, 2022•Remarks by Dr. Shmuel Yitzhaki, as published in Globes, an Israeli business newspaper
RADNOR, Pa., Feb. 11, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today reported remarks by Dr. Shmuel Yitzhaki, Director of the...
-
February 2, 2022
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP (or the "Company"), a Delaware corporation, today announced that it has closed its previously announced private placement priced at a premium to market...
Click here to view our corporate presentation or on the image below